세계의 얼굴용 주사제(보톡스) 시장 보고서 : 제품 유형, 용도 유형, 용도, 최종 사용자 및 지역별(2024-2032년)

The global facial injectables market size reached US$ 8.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 17.7 Billion by 2032, exhibiting a growth rate (CAGR) of 8.3% during 2024-2032. The facial injectables market is driven by the growing aging population, and the increasing demand for non-invasive solutions among individuals, and celebrity endorsements and social media influence driving demand for aesthetic treatments worldwide.

Facial Injectables Market Analysis:

Major Market Drivers: The market growth is propelled by the increasing demand for minimally invasive cosmetic procedures, increasing awareness of facial aesthetics, and the desire of the aging population to appear youthful.

Key Market Trends: The demand for non-surgical procedures such as Botox and dermal fillers is increasing as a result of their efficiency and minimal level of downtime. In the facial injectables market forecast, the industry will witness the ongoing creation of diverse product formulations and application options influenced by the increased desire to attain natural-looking results and to offer patients treatments that are effective safe customized.

Geographical Trends: North America is the largest market due to high disposable income, well-developed healthcare infrastructure, and widespread adoption of aesthetic treatments. Other potential markets include Asia-Pacific and Europe, where residents' income is increasing, followed by stringent regulations, and hundreds of aesthetic clinics providing injectable treatment.

Competitive Landscape: Some of the major market players in the facial injectables industry include Allergan Plc, Anika Therapeutics Inc., Bloomage BioTechnology, Johnson & Johnson, Galderma Pharma S.A., Integra LifeSciences, Ipsen (Mayroy SA), Medytox Inc., Merz Holding GmbH & Co. KG, Prollenium Medical Technologies Inc., Sanofi, SciVision Biotech Inc., Sinclair Pharma (Huadong Medicine Co. Ltd.), Suneva Medical Inc. and Bausch Health Companies Inc. among many others.

Challenges and Opportunities: The regulatory hurdles and safety concerns pose challenges for market players, necessitating stringent compliance with quality standards and transparent communication with consumers. As outlined in the facial injectables market overview, eexpansion into untapped markets, such as emerging economies and male aesthetic procedures, offers avenues for growth amidst intensifying competition and market saturation in traditional segments.

Facial Injectables Market Trends:

Increasing Aging Population:

As the global population is aging the demand for facial injectables is rising. While they are essential, aging comes with various visible signs like wrinkles, fine lines, and sagging skin. Thus, individuals always opt for aesthetic treatments to keep a youthful appearance. Due to the zero downtime and non-surgical procedure, facial injectables encourage a wide audience inquiring about self-rejuvenation without undergoing invasive treatments. Furthermore, the age sector in developed countries is expanding, and people now care more about their appearance. Hence, they are willing to seek aesthetic treatments to look and feel their best, influencing the facial injectables market outlook. In 2020, the global population aged 60 years and above exceeded the under-five children, according to the World Health Organization. The aging population is expected to double globally from 12% in 2015 to 22% in 2050.

Rising Demand for Non-Invasive Procedures

Individuals are opting for non-invasive facial plastic procedures owing to their convenience, minimal downtime decreased risk, and fewer side effects. For example, dermal fillers and botulinum toxin injections, are injectables that provide quick and efficient solutions to numerous common aesthetic problems like wrinkles, volume depletion, and facial asymmetry. Moreover, busy lives, and technological advances that make many procedures efficient and less dangerous, influence the new generation of non-invasive face treatments, which is increasing the facial injectables market value. Data from the American Society of Plastic Surgeons (ASPS) reveals that a total of 26.2 million surgical and minimally invasive cosmetic and reconstructive treatments were performed in the United States in 2022. It also reveals that 19% of cosmetic surgeries surged since 2019, increasing the facial injectables market demand.

Celebrity Endorsements and Social Media Influence

Beauty standards and consumer preferences are influenced by celebrity endorsements and social media personalities which is driving the facial injectables market growth. When celebrities openly discuss their facial plastic surgeries or post about them on various social media sites, their followers are more likely to consider using facial injectables. For instance, according to the survey by the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS), facial plastic surgeons have reported a 90% rise in facelifts since 2019. Last year, facelifts were the leading surgical procedure for females, with 86% of surgeons performing them. Noses jobs or rhinoplasty come second, with surgeons performing them on 79%, while blepharoplasty or eye lift stood at 73%. For both genders, the top three surgical procedures are rhinoplasty accounting for 83%, blepharoplasties at 49%, and facelifts and partial facelifting at 48%.

Facial Injectables Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product type, application type, application, and end user.

Breakup by Product Type:

Collagen

Hyaluronic Acid (HA)

Botulinum Toxin Type A

Calcium Hydroxylapatite (CaHA)

Polymethylmethacrylate Beads (PMMA Microspheres)

Poly-L-Lactic Acid (PLLA)

Others

Botulinum toxin type A accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the product type. This includes collagen, hyaluronic acid (HA), botulinum toxin type A, calcium hydroxylapatite (CaHA), polymethylmethacrylate beads (PMMA microspheres), poly-l-lactic acid (PLLA), and others. According to the report, botulinum toxin type A represented the largest segment.

Botulinum toxin type A comprises the largest segment due to its wide use to address several cosmetic concerns, including wrinkles, fine lines, and facial asymmetry. Botulinum toxin type A injections, such as Botox, Dysport, and Xeomin, provide a sophisticated, temporary solution by relaxing facial muscles and ensuring smoother and younger-looking skin. Currently, consumer demand for minimally invasive cosmetic procedures continues to rise driving the production of existing product lines. For example, in March 2024, Croma's Korean toxin product manufacturer and partner Hugel was approved by the U.S. Food and Drug Administration for Letybo(R) (LetibotulinumtoxinA) to treat glabellar lines in adults.

Breakup by Application Type:

Aesthetics

Therapeutics

Aesthetics holds the largest share of the industry

A detailed breakup and analysis of the market based on the application type have also been provided in the report. This includes aesthetics and therapeutics. According to the report, aesthetics accounted for the largest market share.

The aesthetic segment includes cosmetic procedures to improve the overall appearance of the face and address signs of aging. With the rise of beauty cultures supported by injectable technologies, which made it possible to offer safe and effective minimally invasive treatments to the patient, more people have opted to undergo such procedures. As per the American Society of Plastic Surgeons (ASPS), facelifts grew by 8%. The survey conducted in 2022 by the International Society of Aesthetic Plastic Surgery presents such results that the trends showed a continued increase in aesthetic surgery, with a significant increase of 41.3% in the last four years. As a result, the increasing facelift procedures are contributing to the facial injectables market growth.

Breakup by Application:

Facial Line Correction

Lip Augmentation

Face Lift

Acne Scar Treatment

Others

The report has provided a detailed breakup and analysis of the market based on the application. This includes facial line correction, lip augmentation, face lift, acne scar treatment, and others.

Facial injectables are commonly used for correcting fine lines, wrinkles, and deep creases in the facial skin to give the patient a fresher and smoother look. Areas of application include the forehead, crow's feet in the eye region, and nasolabial folds, among others, ensuring a natural result that gives the face its youthful curves.

Injectable fillers are also used in lip augmentation to increase the size, give it shape, and maintain a harmonic proportion with the face. Sometimes patients use fillers to get a fuller look, to correct lipstick creases due to aging, or to give better shape and proportion to the lip. Liposuction was the most common surgical procedure according to the International Society of Aesthetic Plastic Surgery (ISAPS) in 2022, with more than 2.3 million procedures and a 21.1% expansion.

Additionally, fillers can recreate a similar effect as surgery in a non-invasive way. This simply an increase in volume in any area of the face that has undergone a deficit and subsequent sagging in the jaw, cheek, or temple areas. Filler injectables result in a lifted and rejuvenated appearance of the face at a reduced risk of postoperative complications and a faster recovery time for the patient. Besides this, injectable fillers are also used in correcting depressed acne scars and restoring the confidence of numerous individuals.

Breakup by End User:

Hospitals

Dermatology Clinics

Others

Hospitals exhibit a clear dominance in the market

A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes hospitals, dermatology clinics, and others. According to the report, hospitals accounted for the largest market share.

The hospital often acts as a one stop space for various medical and cosmetic procedures, facilitating facial injectables among their services. As a result of accessibility and the credibility associated with hospitals, the institutions have attracted a broad patient spectrum. Patients seeking professional care and skills easily obtain their services at a hospital. One report by the International Society of Aesthetic Plastic Surgery (ISAPS) indicated an overall 11.2% of procedures performed by plastic surgeons in 2022, involving 14.9 million surgical and 18.8 million non-surgical procedures performed all over the world. As people embrace surgery restoration procedures the hospital helps numerous individuals' needs for aesthetic treatments, thus generating facial injectables market revenue. Hospitals have adequate and sophisticated tools and well-trained professionals to administer facial injectables.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest facial injectables market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for facial injectables.

As per the facial injectables market research, North America is dominating the market for several reasons resulting in its strong growth. This is mainly due to a large aging population, high disposable income, advanced healthcare facilities, and the pressure to remain young and beautiful among several individuals. Moreover, continuous innovation and technological advancements by key players have sustained the market expansion. In May 2023, Evolus, Inc., a performance beauty organization that delivers innovative products with exceptional experiences to consumers, entered into an exclusive distribution agreement in the United States for five novel dermal fillers with advanced stages of development.

Competitive Landscape:

The facial injectables market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the facial injectables industry include Allergan Plc, Anika Therapeutics Inc., Bloomage BioTechnology, Johnson & Johnson, Galderma Pharma S.A., Integra LifeSciences, Ipsen (Mayroy SA), Medytox Inc., Merz Holding GmbH & Co. KG, Prollenium Medical Technologies Inc., Sanofi, SciVision Biotech Inc., Sinclair Pharma (Huadong Medicine Co. Ltd.), Suneva Medical Inc. and Bausch Health Companies Inc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Key players in the facial injectables market are taking vital steps to ensure the growth of the sector. As a result, companies such as Allergan, Galderma, Longtai, and Sinclair have ensured they have an extensive product portfolio by developing new formulations. They are also expanding their market reach by entering into agreements and partnerships with medical device companies. The promotional programs will help increase consumer awareness about the benefits of using facial injectables, benefiting the injectables sub-sector. For instance, Galderma, launched FACE by Galderma(TM) in Dallas envisioning it as an advanced aesthetic visualization tool driven by augmented reality (AR), the inventive initiative enables aesthetic experts and patients to foretell injectable treatment results even before the procedure. Galderma aims to provide a simulated before and after image of what the scope of each needle can achieve and hopefully alleviate patient anxieties concerning injectable outcomes.

Facial Injectables Market News:

March 2024: Allergan Aesthetics, an AbbVie company, announced that the U.S. FOOD and DRUG ADMINISTRATION (FDA) had approved JUVEDERM(R) VOLUMA(R) XC hyaluronic acid (HA) filler to inject into the temple of a patient identified for moderate to severe temple hollowing in adults over the age of 21. This is the sole HA filler that the FDA has authorized with optimal treatment that is clinically documented to endure up to 13 months.

October 2023: Sinclair Pharma Details, a wholly owned subsidiary of Huadong Medicine Co., Ltd., declared the formation of a strategic partnership with ATGC Pharmacological Research to establish a rational licensing arrangement. Sinclair has been granted exclusive rights to manufacture and commercialize ATGC's botulinum toxin product, ATGC-110, cutting-edge botulinum toxin type A, undergoing clinical development for temporarily enhanced glabellar appearances at moderate to severe levels. It has been exclusively licensed globally (excluding India and South Korea).

Key Questions Answered in This Report

• 1. What is the global facial injectables market growth?
• 2. What are the global facial injectables market drivers?
• 3. What are the key industry trends in the global facial injectables market?
• 4. What is the impact of COVID-19 on the global facial injectables market?
• 5. What is the global facial injectables market breakup by product type?
• 6. What is the global facial injectables market breakup by application type?
• 7. What is the global facial injectables market breakup by end user?
• 8. What are the major regions in the global facial injectables market?
• 9. Who are the key companies/players in the global facial injectables market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Facial Injectables Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product Type

• 6.1 Collagen
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Hyaluronic Acid (HA)
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Botulinum Toxin Type A
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Calcium Hydroxylapatite (CaHA)
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Polymethylmethacrylate Beads (PMMA Microspheres)
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Poly-L-Lactic Acid (PLLA)
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast
• 6.7 Others
  • 6.7.1 Market Trends
  • 6.7.2 Market Forecast

7 Market Breakup by Application Type

• 7.1 Aesthetics
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Therapeutics
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Application

• 8.1 Facial Line Correction
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Lip Augmentation
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Face Lift
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Acne Scar Treatment
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Others
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by End User

• 9.1 Hospitals
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Dermatology Clinics
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Others
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Allergan Plc
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Anika Therapeutics Inc.
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 SWOT Analysis
  • 15.3.3 Bloomage BioTechnology
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
  • 15.3.4 Johnson & Johnson
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 Galderma Pharma S.A.
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 SWOT Analysis
  • 15.3.6 Integra LifeSciences
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 Financials
    • 15.3.6.4 SWOT Analysis
  • 15.3.7 Ipsen (Mayroy SA)
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
  • 15.3.8 Medytox Inc.
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
  • 15.3.9 Merz Holding GmbH & Co. KG
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
  • 15.3.10 Prollenium Medical Technologies Inc.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
  • 15.3.11 Sanofi
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
    • 15.3.11.4 SWOT Analysis
  • 15.3.12 SciVision Biotech Inc.
    • 15.3.12.1 Company Overview
    • 15.3.12.2 Product Portfolio
    • 15.3.12.3 Financials
  • 15.3.13 Sinclair Pharma (Huadong Medicine Co. Ltd.)
    • 15.3.13.1 Company Overview
    • 15.3.13.2 Product Portfolio
  • 15.3.14 Suneva Medical Inc.
    • 15.3.14.1 Company Overview
    • 15.3.14.2 Product Portfolio
  • 15.3.15 Bausch Health Companies Inc.
    • 15.3.15.1 Company Overview
    • 15.3.15.2 Product Portfolio
    • 15.3.15.3 Financials
    • 15.3.15.4 SWOT Analysis